AOD-9604 in Saint Clare — Fat Loss Peptide Research Guide
AOD-9604 research guide for Saint Clare. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 in Saint Clare — Research & Sourcing Guide
For anyone in Saint Clare looking to source AOD-9604, the first thing to know is that this compound is available only through an online research supply market. The benefit of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers better verification tools than any local market ever offers. Vendors worth sourcing from proactively publish batch-matched Certificates of Analysis documenting HPLC purity analysis, mass spec identity confirmation, endotoxin levels, and residual solvent results — all for the specific lot you are purchasing. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Saint Clare researcher needs to source confidently.
Understanding AOD-9604 — Biology & Evidence
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Saint Clare researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
AOD-9604 Purchasing Guide
Before assessing any particular supplier, establish a quality benchmark — so you can recognise whether a vendor meets it. When reviewing a AOD-9604 COA, verify: the batch number matches your product, HPLC purity is ≥98%, mass spec identifies the correct molecular weight, and endotoxin levels are at acceptable levels for the intended application. Signs of a credible vendor beyond COA quality: established track record of at least two years, responsive technical support who understand testing methodology, and shipping with desiccant and appropriate cold protection. The lyophilised (freeze-dried) form of AOD-9604 is much more stable than liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations lose activity within weeks.
Order AOD-9604 — ships to Saint Clare
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Temperature excursions — even temporary temperature deviation — can compromise product integrity without detectable changes to appearance; always maintain cold chain and work with cold-shipped material. The main safety concern arising from sourcing in AOD-9604 research is bacterial endotoxin from low-quality material — a verified endotoxin panel in the batch COA is the specific protection against this risk. PubMed represent the most comprehensive research databases for AOD-9604 research; prioritise peer-reviewed studies with characterised source material over unreviewed preprints or forum reports.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
